LOS ANGELES--(BUSINESS WIRE)--Los Angeles-based The Angeles Clinic and Research Institute today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab. The Angeles Clinic and Research Institute was a key site and played a leadership role in the clinical trial, which was sponsored by Bristol-Myers Squibb.
